Patents by Inventor Gregroy Hardee

Gregroy Hardee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oral delivery of therapeutically effective LNA oligonucleotides
    Patent number: 9566293
    Abstract: The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA oligomer is administered in the presence of a penetration (permeation) enhancer.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: February 14, 2017
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Gregroy Hardee, Ellen Marie Straarup, Marie Wickstrom Lindholm, Henrik Orum, Henrik Frydenlund Hansen
  • Oral delivery of therapeutically effective LNA oligonucleotides
    Patent number: 9364495
    Abstract: The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA oligomer is administered in the presence of a penetration (permeation) enhancer.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: June 14, 2016
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Gregroy Hardee, Ellen Marie Straarup, Marie Wickstrom Lindholm, Henrik Orum, Henrik Hansen
  • Oral Delivery of Therapeutically Effective LNA Oligonucleotides
    Publication number: 20160032289
    Abstract: The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA oligomer is administered in the presence of a penetration (permeation) enhancer.
    Type: Application
    Filed: October 19, 2015
    Publication date: February 4, 2016
    Inventors: Gregroy Hardee, Ellen Marie Straarup, Marie Wickstrom Lindholm, Henrik Orum, Henrik Frydenlund Hansen
  • ORAL DELIVERY OF THERAPEUTICALLY EFFECTIVE LNA OLIGONUCLEOTIDES
    Publication number: 20120322851
    Abstract: The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA oligomer is administered in the presence of a penetration (permeation) enhancer.
    Type: Application
    Filed: October 20, 2010
    Publication date: December 20, 2012
    Inventors: Gregroy Hardee, Ellen Marie Straarup, Marie Wickstrom Lindholm, Henrik Orum, Henrik Hansen